ストックスクリーナーアプリを入手
33.06
0.63%
-0.21
前日終値:
$33.27
開ける：
$32.91
24時間の取引高:
134.12K
Relative Volume:
0.37
時価総額：
$2.18B
収益：
$282.04M
当期純損益:
$221.88M
株価収益率:
9.8223
EPS:
3.3658
ネットキャッシュフロー:
$-449.57M
1週間 パフォーマンス:
+7.16%
1か月 パフォーマンス:
+18.11%
6か月 パフォーマンス:
+43.74%
1年 パフォーマンス:
+23.96%
1日の値動き範囲:
$32.79
$33.23
1週間の範囲:
$31.02
$33.66
52週間の値動き範囲:
$22.36
$33.66
Galapagos Nv Adr Stock (GLPG) Company Profile
GLPG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
33.10 | 2.16B | 282.04M | 221.88M | -449.57M | 3.3658 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.84 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.48 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.29 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.75 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
302.90 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2024-11-20 | ダウングレード | Kepler | Hold → Reduce |
| 2024-09-09 | 開始されました | Leerink Partners | Market Perform |
| 2024-08-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-03-28 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-03-07 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-08-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-01-23 | アップグレード | Jefferies | Underperform → Hold |
| 2022-11-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-27 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-19 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-08-06 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-04-20 | 開始されました | Deutsche Bank | Buy |
| 2021-04-14 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-02-23 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-02-19 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-02-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-19 | 開始されました | Maxim Group | Buy |
| 2020-10-21 | ダウングレード | Goldman | Neutral → Sell |
| 2020-08-25 | ダウングレード | Jefferies | Buy → Hold |
| 2020-08-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-08-19 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-08-19 | アップグレード | Citigroup | Neutral → Buy |
| 2020-07-10 | ダウングレード | Stifel | Buy → Hold |
| 2020-03-30 | アップグレード | Jefferies | Hold → Buy |
| 2020-03-18 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2020-02-25 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2020-02-24 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2020-02-20 | ダウングレード | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-01-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-12-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-12-17 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-12-02 | 開始されました | BofA/Merrill | Neutral |
| 2019-09-09 | 再開されました | Morgan Stanley | Overweight |
| 2019-07-31 | アップグレード | UBS | Neutral → Buy |
| 2019-07-29 | ダウングレード | Jefferies | Buy → Hold |
すべてを表示
Galapagos Nv Adr (GLPG) 最新ニュース
Raymond James reiterates Market Perform rating on Galapagos stock - Investing.com
Raymond James reiterates Market Perform rating on Galapagos stock By Investing.com - Investing.com South Africa
Planisware expands into Belgium to support the sustained growth of its business in the Benelux region - GlobeNewswire Inc.
Galapagos stock holds as CEO change, spinoff plans halted By Investing.com - Investing.com India
Galapagos stock holds as CEO change, spinoff plans halted - Investing.com
Ratios in Focus: Analyzing Galapagos NV ADR (GLPG)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Galapagos stock holds Market Perform rating at Raymond James - Investing.com
Galapagos To Spin Off Innovative Medicines Business - Forbes
Belgium stocks higher at close of trade; BEL 20 up 0.06% - Investing.com
Galapagos stock downgraded to Reduce on strategic concerns - Investing.com
Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats - Investor's Business Daily
Earnings call: Galapagos outlines strategic focus in Q1 2024 results - Investing.com
Billionaire hedge fund manager David Einhorn’s portfolio revealed - Daily Investor
+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients - Barchart.com
Galapagos NV announces retirement of CEO - Seeking Alpha
Galapagos Gets First Commercial Drug With Jyseleca Approval - Yahoo Finance
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology - Yahoo Finance
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts - Yahoo Finance
AIM tech shares that broke America - Interactive Investor
GLPG Stock Price and Chart — EURONEXT:GLPG - TradingView
The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes
Galapagos Nv Adr (GLPG) 財務データ
収益
当期純利益
現金流量
EPS
1.69%
0.05%
大文字化:
|
ボリューム (24 時間):